Blue Eye Soft Receives Permission for AI-Driven Diagnosis Software

Blue Eye Soft, an innovative IT-solutions and software development company, announced that it has received acknowledgment from the U.S. Food and Drug Administration (FDA) of its Pre-Submission package for its proprietary artificial intelligence (AI)-driven medical imaging software, BLUEDOCAI^TM, to assist with the medical diagnosis of diseases such as COVID-19.

BLUEDOCAI^TM is a clinical decision support tool that uses AI-driven deep learning algorithms to assist radiologists and other healthcare professionals with fast and accurate diagnosis of diseases, such as COVID-19. BLUEDOCAI^TM has the capability to rapidly analyze chest X-rays to detect the presence of COVID-19 with >90% accuracy and may therefore help improve the efficiency and accuracy of radiology departments in the wake of the overwhelming workload caused by the COVID-19 pandemic.

Blue Eye Soft Corp is also developing tools to support the medical diagnosis of other diseases such as pneumonia, pneumothorax, tuberculosis, cancer, and stroke which may have the potential to be used with a variety of medical imaging technologies across different hospital settings and locations. The pioneering technology behind BLUEDOCAI^TM is based on well-established medical image processing research of Russell C Hardie, PhD and Barath Narayanan, PhD and is currently licensed by Blue Eye Soft.

In addition, Blue Eye Soft has announced that the U.S. Department of Commerce Bureau of Industry and Security has approved the commodity license for BLUEDOCAI^TM, which will allow for its international export. The Blue Eye Soft team believes this is an important step forward for a company rooted in South Carolina to be able to export locally developed AI-powered diagnostic technology beyond the United States. Srikanth Kodeboyina, CEO of Blue Eye Soft said, “Our team at Blue Eye Soft is looking forward to serving as a pivotal partner for radiology departments worldwide, helping them deliver precise and high-value patient care — even in the challenging times of this ongoing pandemic.”